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Background: Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease, with a worldwide
prevalence of 0.5% to 1%. Anti-cyclic citrullinated peptide antibody (anti-CCP-2 Ab) is a marker of choice for diagnosing
early and late RA. Anti-oxidant enzymes activity decreases in RA patients. Till now, the relationship between the
rheumatoid factor (RF) and anti-CCP-2 Ab, anti-oxidant activity and polymorphism of paraoxenase-1 (PON-1) 192 Q/R in
patients with RA has not been investigated. In this study, we aimed to determine the serum level of RF and anti-CCP-2
Ab, PON-1 activity and 192 Q/R polymorphism and arylesterase (ARE) activity in patients with RA. Also, we studied RA
markers in different genotypes of PON-1 of RA patients.
Methods: A total of 120 RA patients and 90 healthy persons were subjected to full clinical examinations and routine
laboratory tests. PON-1 and ARE activities were determined using an enzymatic spectrophotometric method. PON-1
192 gene polymorphism was determined using polymerase chain reaction based restriction fragment analysis. RF was
measured by immunoturbidimetry method and anti-CCP-2 Ab was assayed by enzyme-linked immunosorbent assay
(ELISA). Statistical analysis was performed using SPSS for windows 20.0.
Results: The sensitivity and specificity of anti-CCP-2 Ab for the diagnosis of RA were 76.2% and 100% respectively.
PON-1 and ARE activities were statistically lower (P <0.001) in the RA group compared to the control group. A negative
correlation between RF and anti-CCP-2 Ab levels and PON-1 and ARE activities was found. No significant difference in
the genotype distribution between RA patients and healthy persons was detected. RF and anti-CCP-2 Ab levels were
higher in RA patients carried RR genotype than in those carried QQ genotype.
Conclusion: High RF and anti-CCP-2 antibody serum levels were found to be associated with decreased PON-1 and
ARE activities with no correlation between PON-1 polymorphism and serum levels of RF and anti-CCP-2 Ab in patients
with RA. These results may indicate an implication between antioxidant enzymes activity and serum levels of RF and
anti-CCP-2 Ab.
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Rheumatoid arthritis (RA) is a chronic multisystem dis-
ease of unknown cause characterized by chronic polyar-
thritis and can lead to deformities and disabilities. Early
intervention is crucial in preventing irreversible joint
damage, so it is important to diagnose RA at very early
stage in the disease [1]. When often not all clinical
symptoms are manifested, so, good serological markers* Correspondence: afatani@kau.edu.sa
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unless otherwise stated.are needed. Anti-CCP-2 Ab is a marker of choice for
diagnosing early RA as it appears to be highly specific
and sensitive for the disease comparable to other tests
such as RF test. Furthermore, anti-CCP-2 Ab positivity
can predict future development of RA in both asymp-
tomatic individuals and in patients with undifferentiated
arthritis. Moreover, its antibody level at presentation can
correlate with progression to erosive disease [2].
Although the exact pathogenesis of the disease is un-
known, both genetic and environmental factors play key
roles in the disease process [3]. It has been reported thatoMed Central Ltd. This is an Open Access article distributed under the terms of
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role in the pathogenesis of RA [4,5]. Under normal cir-
cumstances, relatively low concentrations of ROS are
formed in all cells and tissues in oxidative processes and
a variety of antioxidative mechanisms serve to control
their production [6]. Under pathological conditions, the
levels of ROS are altered by increased production and/or
inadequate removal by antioxidants such as paraoxonase
enzyme (PON).
The paraoxonases (PON) gene family consists of three
members; PON-1, PON-2, and PON-3 located adjacent to
each other on the long arm of human chromosome num-
ber 7. These three human PON genes share approximately
60% identity at the amino acid level and approximately
70% identity at the nucleotide level [7]. Human serum
PON-1 is a calcium dependent glycoprotein which is
tightly associated with high density lipoprotein HDL [8].
PON-1 decreases accumulation of the lipid peroxides in
low density lipoprotein (LDL) due to its ability to reduce
ROS and attenuates the biological effects of mildly oxidized
LDL [9]. PON-1 serum activity appears to be different
among individuals and populations. The molecular basis of
such variations may be due to polymorphism in PON-1
gene. PON-1 has two polymorphisms at the coding region;
one in position 192, which is a glutamine/arginine substitu-
tion and the other at position 55 which is a methionine/
leucine substitution [10]. These polymorphisms may affect
the hydrolytic activity of PON- 1 isoenzymes with respect
to lipid peroxidation. It has been reported that paraoxo-
nase activity of the glutamine 192 (Q allele) isoforms is
lower than that of the arginine 192 (R allele) isoforms [11].
Nevertheless, PON-1 in QQ subjects seems to be more ef-
fective in protecting LDL from oxidation than that in RR
genotype subjects. Although the relationship between
PON-1 192 activity and polymorphism in rheumatoid arth-
ritis was investigated, the correlation between the serum
levels of RF and anti-CCP-2 Ab and PON-1 192 activity
and polymorphism is not cleared. So, the main aim of the
present work was designed to investigate the relationship
between gene PON-1 192 polymorphism and serum PON-
1 and ARE activities and the serum levels of RF and anti-
CCP-2Ab in RA patients.
Methods
Patients
This study was carried out on 210 individuals, classified
into two groups. Group I: 120 patients with RA with
duration of the disease ranged from 4 to 12 years.
They were 90 females (75%) and 30 males (25%). Their
ages ranged from 18 to 62 years with a mean value of
41.33 ± 15.93 years. The patients fulfilled the 1987 revised
American College of Rheumatology criteria for RA. Pa-
tients were selected from the out patients’ clinics at differ-
ent Jeddah’s hospitals including King Abdulaziz UniversityHospital. Group II: 90 healthy controls without joint com-
plaints or any rheumatological disease; 60 females (66.66%)
and 30 males (33.33%). Their ages ranged from 19 to
64 years with a mean value of 40.5 ± 17.56 years.
Exclusion criteria
Patients having diseases overlapping with other connective
tissue diseases like systemic lupus erythematosus (SLE),
systemic sclerosis, polymyositis and those suffering from
renal diseases, hypertension, ischemic heart disease, HIV
and smokers were excluded from the study. Patients were
subjected to complete history taking, full clinical examina-
tions and radiological and routine laboratory investigations.
Patients underwent; clinical assessment of disease activity
by full history taking, general and local examinations,
measurement of the 28-joint count of tender and swol-
len joints with calculation of the disease activity score
(DAS-28) for each RA patient by DAS-28 score calculator.
Written informed consents were obtained from all patients
and controls according to the Declaration of Helsinki
and the study was approved ethically by Committee of the
Department of Medical Microbiology and Parasitology,
Faculty of Medicine, King Abdulaziz University, Jeddah,
Kingdom of Saudi Arabia.
Sampling
Blood samples were collected from all patients and controls
and divided into 2 parts; one for genetic study and the other
part of the plasma was separated and stored at −70°C for
serological and enzymatic studies. The sample for genetic
study was put in sterile K3EDTA (tri-potassium ethylene-
diamine tetraacetic acid) coated tubes which were used
for the DNA extraction. White cells were removed from
the buffy coat for DNA extraction. Samples were stored
at −20°C till the time of use.
Laboratory tests
a- Determination of rheumatoid factor (RF)
RF was measured by immunoturbidimetry using Cobas
integra RFII (Roche Diagnostics GmbH, Mannheim,
Germany) according to the instructions of the manufac-
turer. Positivity is ≥20 IU/ml.
b- Determination of serum anti-CCP- 2 antibodies
Anti-CCP-2 Ab was detected by ELISA (DIASTAT Axis-
Shield, Dundee, United Kingdom) according to the in-
structions of the manufacturer. Positivity is ≥5 U/ml.
c- Determination of serum PON-1 activity
PON-1 activity was measured by adding plasma to Tris
buffer (100 mmol/l, pH 8.0) containing 2 mmol/l CaCl2
and 1 mmol/l paraoxon (O, O-diethyl-O-nitrophenylpho-
sphate (Sigma). The rate of generation of P-nitrophenol
was determined at 405 nm, 25°C with the use of
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previously [12,13].
d- Determination of serum arylesterase (ARE) activity
Arylesterase (ARE) activity was measured using phenyla-
cetate as a substrate as previously described [14]. The ini-
tial rates of hydrolysis were determined by following the
increase of phenol concentration at 270 nm at 37°C on a
CE 7250 spectrophotometer (Cecil Instruments Limited,
UK). Enzyme activities were expressed in international
units per 1 liter of serum (U/l).
e- Determination of PON-1 genotypes
DNA was extracted from peripheral leukocytes using
sodium dodecyl sulphate (SDS) lysis and ethanol preci-
pitation [15]. Aliquots of genomic DNA were used for
PCR amplification as described previously [16,17]. Two
primers, the sense primer: 5′ TAT TGT TGC TGT GGG
ACC TGA G 3′ and antisense primer: 5′ CAC GCT AAA
CCC AAA TAC ATC TC 3′ were used for PCR amplifica-
tion of 99 bp DNA fragment covering the region contain-
ing Gln192 or Arg 192. The PCR reaction mixture
contained about 200 ng DNA template, 0.5 μM of each
primer, 1.5 mM MgCl2, 200 μM of the 4 dNTP and 1 U
Taq DNA polymerase (Amersham, Bioscience). After de-
naturing the DNA for 4 minutes at 95°C, the reaction mix-
ture was subjected to 35 cycles of denaturing for 1 minute
at 95°C, 1 minute annealing at 60°C and 1 minute exten-
sion at 72°C. The 99 bp PCR products were digested with
8 U Alw1 restriction endonuclease (MBI Fermentas) over-
night at 37°C and the digested products were separated by
electrophoresis on 2% agarose electrophoresis and visual-
ized using ethidium bromide. The Arg genotype contains
a unique Alw1 restriction site which results in 66 and
33 bp products, whereas the Gln genotype will not be
cleaved by this restriction enzyme.
Statistical analysis
This was performed using SPSS for windows 20.0 (SPSS
Inc, Chicago. IL, USA). Student’s t test was used to com-
pare mean values of continuous variables in cases and
controls, whereas χ2 analysis was used to compare cat-
egorical data. Correlation between variables was evaluated
using Pearson (r) correlation coefficient. Relative risk was
performed to examine genotype risk contribution.
Results
Table 1 showed that the ages of patients were matched
with ages of controls. The ratio of female to male in RA
patients was more than that in controls. As regarding
ESR, RF PON-1, ARE activities and anti-CCP-2 Ab there
was significant changes in RA patients when compared
to controls.The clinical characteristics of the 120 RA patients are
shown in Table 2. Patients had a moderate-active dis-
ease as shown by the high DAS (4.18 ± 1.73) and HAQ
(1.6 ± 0.64) scores. Moreover, one hundred and five pa-
tients were treated by (disease-modifying anti-rheumatic
drugs (DMARDs). Overall, 95 patients were receiving ste-
roid therapy.
Table 3 showed a negative correlation between PON-1
and ARE enzymatic activity and serum levels of RF and
anti-CCP-2 Abs.
Table 4 showed no significant difference in distribution
of QQ, QR and RR genotypes between both RA patients
and controls. However, there was a significant correlation
between PON-1 activity and genotypes. Also, Table 4
showed Q and R allele’s frequency in PON-1 in the RA pa-
tients which was 76.26% for Q allele and 23.74% for R al-
lele; meanwhile, it was 74.44% for Q and 25.56% for R in
controls. RR and OR equations did not show a significant
risk between RA patients and controls.
Table 5 showed a significant increase of PON-1 activity,
serum levels of RF and anti-CCP-2 Ab in RA patients car-
ried RR genotype compared to QQ genotype. While re-
garding the ARE activity; no significant difference was
detected in RA patients with RR alleles compared to QQ
genotype.
Discussion
In the present work, the diagnostic value of antibodies
anti-CCP-2 Ab and RF in the diagnosis of rheumatoid
arthritis (RA) was evaluated. Furthermore, the relation-
ship between the gene polymorphism of PON-1 and its
enzyme activity, ARE enzyme activity and serum levels
of RF and anti-CCP-2 Ab were investigated. In our
study, the mean concentration of RF was 149.34 ±
64.30 IU/ml and 54.76% of the RA patients were sero-
positive. The serum concentrations of RF were more
than that reported by Mansour et aI [18] and similar to
that of Kim et al. [19]. The sensitivity and specificity of
RF were 30% and 70% respectively. Our results did not
match with the results of Choi at all and Greiner et al.
[20,21]. This can be attributed to the different methods
used for RF measurement, selection of cases, disease du-
rations and administration of different drugs.
Anti-CCP-2 antibody is a marker of choice for diag-
nosing early RA as it appears to be highly specific for
the disease. Furthermore, the emerging data strongly
suggest that anti-CCP-2 antibodies have the power to
predict the development of RA in patients with early
and undifferentiated arthritis, the severity of disease in
patients with established RA and the possibility of future
onset of RA in certain high-risk populations [22]. In our
study, the mean concentration of anti-CCP-2 Abs was
62.54 ± 21.22 U/mL in all RA patients (71.8% were sero-
positive) which was similar to that detected by Kim et al.
Table 1 Demographic pattern and laboratory results of
RA patients and controls
Parameters RA patients Controls t-test P value
Number (F/M) 120 (90/30) 90 (60/30) - NS
Age (years) 41.33 ± 15.93 40.5 ± 17.5 0.36 NS
Duration of
illness (years)
9.65 ± 4.28 0.0 - -
ESR (1st hr)
mm/hr
41.62 ± 8.02 8.65 ± 2.89 17.21 0.001*
RFMean ± SE
(IU/mL)




62.54 ± 21.22 4.41 ± 1.20 19.85 0.001*
PON-1 activity
(nmol/min/ml)
64.44 ± 11.33 152.18 ± 17.74 16.25 0.001*
ARE activity
(Um/l)
197.65 ± 83.84 363.65 ± 169.15 10.52 0.001*
Data are presented as mean ± SD. NS means not significant.
P value was calculated by t-test P* value was significant at <0.001.
Table 3 Correlation coefficient study between enzymes
activity and RA biomarkers






r 0.66 −0.77 −0.85
P 0.001* 0.001* 0.001*
ARE (U/l) r 0.23 0.36
p 0.156 0.18
RF (IU/ml) r 0.77
P >0.001*
P* value was significant at <0.001.
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[23]. As regards anti-CCP-2 Ab sensitivity and specificity,
they were 76.2% and 100% respectively. Also, several
authors [24,25] reported similar percentages. However,
Berrocal et al. and Nielen et al. [26,27] found lower sensi-
tivities and specificities for anti-CCP-2 (43% and 85%) and
(57.8% and 94.2%) respectively. Such differences can be
explained by using different ELISA kits with different cut
off values. Anti-CCP-2 Ab serum levels have an additional
diagnostic value over RF in RA patients [28,29]. Another
evidence for superiority of anti-CCP-2 Ab as a good diag-
nostic marker in Saudi patients with RA in comparison
with RF came from the study of Safi et al. [30] who found
that a proportion (30.5%) of RF-negative RA patients, had
positive anti-CCP-2 Ab serum levels. However, the IgM-RF
is still widely used as a screening marker in the diagnosis
of RA. Moreover, anti-CCP-2 Ab assays have a comparableTable 2 Characteristics of RA patients
Parameters (mean ± SD) RA patients
Positive RF, n (%) 65 (54.28%)
Positive Anti-CCP-2 Ab, n (%) 83 (69.57%)
Current DMARDs therapy, n (%) 105 (87.5%)
Current steroid therapy, n (%) 95 (79.4%)
Tender joints count (n) 16.6 ± 8.8
Swollen joints count (n) 9.8 ± 5.6
DAS28 4.18 ± 1.73
Pain VAS score 51.25 ± 20.09
HAQ score 1.6 ± 0.64
Values are reported as mean ± SD.
DMARDs: disease-modified anti-rheumatic drugs.
DAS28: disease activity score in 28 joints.
VAS: visual analog scale.
HAQ: Health Assessment Questionnaire.sensitivity in the diagnosis of RA but with a much higher
specificity. The anti-CCP-2 Ab assay has proved to be very
helpful and seems to be the diagnostic marker of choice
for the diagnosis of RA especially for early cases [2,29].
The increase in the serum level of anti-CCP-2 Abs is corre-
lated with the duration of RA and complications [31].
In the present study, PON-1 and ARE activities were
decreased significantly in RA patients compared with
the controls. Such results are in basic agreement to the
previous reports of Altinadg et al., Baskol et al., Isik
et al. and Tanimoto et al., [32-35]. The low PON-1 and
ARE enzymes activities in RA patients may result from
the damage of PON-1 and ARE proteins by the action of
high amount of reactive oxygen species produced in RA
patients rather than reduced synthesis [34]. Further-
more, we demonstrated the relationship between RF,
anti-CCP-2 Abs, PON-1 and ARE where we found a
negative correlation between anti-CCP-2 Ab and antiox-
idative enzymes activities of PON-1 and ARA activity.
Therefore, our study is unique in the investigation of the
relationship between RF and anti-CCP-2 Ab tests and
PON-1 and ARE enzymes. It has been suggested that
anti-CCP-2 Ab may be related to the increase oxidative
activity in RA patients [36,37]. For example, TNF-alpha in-
hibitor acts as a regulator against pentosidine formation,
oxidative DNA damage and lipid peroxidation and is asso-









QQ 70% (84/120) 68.90% (62/90) 0.862* 1.02 1.05
RR 17.5% (21/120) 20% (18/90) 0.644* 0.93 0.85
QR 12.5 (15/120) 11.10% (10/90) 0.758* 1.06 1.14
Allele frequency
Q 183 (76.26%) 134 (74.44%) 0.670* 1.04 1.10
R 57 (23.74%) 46 (25.56%)
P value was calculated by χ2 -test.
P* value was not significant (P>0.05).
Table 5 PON-1, ARE activities, RF and Anti-CCP-2 Ab in
QQ, QR and RR genotypes in the RA patients
Test Q Q Q R R R P value
No = 84 No = 21 No = 15
PON-1 activity
(nmol/min/ml)
56.75 ± 8.62 71.63 ± 6.11 78.56 ± 11.83 0.001*
ARE activity
(U/l)
181.21 ± 80.56 223.34 ± 81.94 178.52 ± 72.09 0.098
RF
(IU/ml)
149.54 ± 35.96 159.40 ± 32.54 188.75 ± 26.81 0.003*
Anti-CCP-2 Ab
(U/ml)
46.91 ± 20.95 62.32 ± 14.73 79.42 ± 12.11 0.0021*
Data are presented as mean ± SD. NS means not significant.
P value was calculated by students -test.
P* value was significant at P <0.05.
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[38,39]. In a similar way; reducction of PON-1 activity may
lead to elevation of anti-CCP-2 Ab. Reduction of PON-1
activity may aggravate ROS formation leading to more lipid
peroxidation, cellular and DNA damage consequently
resulting in more formation of anti-CCP-2 Ab.
In this study, there was no significant difference in the
distribution of Q and R alleles between the RA patients
and controls. By using risk factor equation and Odds ra-
tio we could not able to detect any risk factor between
the RA patients and controls. Therefore, PON-1 Q192R
polymorphism might not be associated with the inci-
dence of rheumatoid arthritis among Saudi population.
This result was in basic agreement with the work of
Hashemi et al. [40] who found no significant differences
between RA Iranian patients and controls. Tanimoto
et al. [35] found that there was a difference in the distri-
bution of PON-1 192 Q/R genotypes among RA Japa-
nese patients and healthy subjects. PON-1 activity was
obviously low among RA patients who carried PON-1 Q
genotype compared with that in healthy subjects despite
the absence of differences in PON-1-R between the two
groups. This discrepancy might be due to the difference
in ethnic groups. In the present study, the QQ genotype
was the major prevailing type in our patient group with
a 70% percentage followed by QR (17.5%) then RR
(12.5%). The Q allele frequency was significantly higher
than R allele in both RA patients and controls. The Q al-
lele carriers were previously reported to be protected
against peroxidation more than R allele carriers [11].
The present study showed a significant difference in
PON-1 activity among RR genotype compared to QQ
and QR genotypes i.e. RR genotype was the most active
towards paraoxon, QQ genotype was the least active,
while the activity of QR genotype was intermediate.
However, no difference was detected in ARE enzyme ac-
tivity among QQ, QR and RR genotypes in RA patients.
Tripi et al. [41] indicated that the PON-1 Q192R poly-
morphism has substantial influence on PON-1 activitytowards paraoxon, which has been reported by many
other investigators.
Our results showed a significant elevation of the serum
levels of RF and anti-CCP-2 Ab in RR genotype compared
to QQ genotype. This novel unique observation was not
demonstrated in previous known studies. The occurrence
of high serum levels of RF and anti-CCP-2 Abs which had
been detected more in RR genotype than in QQ genotype
can be explained by the following five points: (1) It has
been suggested that there is an association between the
high serum levels of anti-CCP-2 Ab and increased oxida-
tive stress in RA patients [39]. (2) The increase of anti-
CCP-2 Ab serum level is strongly associated with both
prevalent tissue erosions and the development of erosions
in RA joint tissues. (3) High serum levels of anti-CCP-2
Abs have been associated with an erosive disease outcome
in RA. (4) RA synovial fluid and tissue have also demon-
strated oxidative damage to hyaluronic acid, low-density-
lipoproteins (LDL), proteins, cartilage, extracellular colla-
gen, and intra-cellular DNA. (5) The PON-l R allele ap-
pears to have a lower capacity to protect against oxidation
of tissue rather than the PON-1Q allele consequently; one
may suggest that the R allele, has a low capacity to protect
tissue from oxidation than that of PON- 1 Q allele.
Conclusions
In conclusion, there is a reduction in PON-1 and ARE ac-
tivities in RA patients. Also, we found a relationship be-
tween high serum levels of RF and anti-CCP-2 Ab and
decreased PON-1 and ARE enzymatic activities in RA pa-
tients. Furthermore, it has been found that there was no as-
sociation between Q192R polymorphism of PON-1 and
RA. Moreover, it has been found a significant increase of
RF and anti-CCP-2 Ab levels in RR genotype compared to
QQ genotype.
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